Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Saved in:
| Title: | Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. |
|---|---|
| Authors: | Penny HL; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Hainline K; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Theoharis N; Labcorp, Translational Biomarker Solutions, Greenfield, IN, United States., Wu B; Department of Biologics, Amgen, Thousand Oaks, CA, United States., Brandl C; Department of Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany., Webhofer C; Department of Process Development, Amgen Research (Munich) GmbH, Munich, Germany., McComb M; Department of Clinical Pharmacology, Modeling & Simulation, Amgen, Thousand Oaks, CA, United States., Wittemer-Rump S; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Koca G; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Stienen S; Department of Early Development (Oncology), Amgen Research (Munich) GmbH, Munich, Germany., Bargou RC; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Hummel HD; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Loidl W; Department of Urology, Ordensklinikum Linz GmbH, Linz, Austria., Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany., Eggert T; Department of Early Development (Oncology), Amgen, Thousand Oaks, CA, United States., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Mytych DT; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Oct 23; Vol. 14, pp. 1261070. Date of Electronic Publication: 2023 Oct 23 (Print Publication: 2023). |
| Publication Type: | Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
